Location of Repository

Systematic Evaluation of the Metabolic to Mitogenic Potency Ratio for B10-Substituted Insulin Analogues

By Tine Glendorf, Louise Knudsen, Carsten E. Stidsen, Bo F. Hansen, Anne Charlotte Hegelund, Anders R. Sørensen, Erica Nishimura and Thomas Kjeldsen
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3285154
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (1994). A model for insulin binding to the insulin receptor.
    2. (1988). A mutant human proinsulin is secreted from islets of Langerhans in increased amounts via an unregulated pathway.
    3. (2003). A novel insulin analog with unique properties: Lys(B3),Glu(B29) insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1.
    4. (1992). A panel of monoclonal antibodies for the type-I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity.
    5. (1987). A superactive insulin: [B10-aspartic acid]insulin(human).
    6. (1990). Action profiles of fast onset insulin analogs.
    7. (2008). Alanine scanning of a putative receptor binding surface of insulin-like growth factor-I.
    8. (1978). Application of four-parameter logistic model to bioassay: Comparison with slope ratio and parallel line models.
    9. (1997). ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: Evidence for enhanced interactions with the insulin-like growth factor-I receptor.
    10. (1992). Carcinogenic effect of the human insulin analog B10Asp in female rats.
    11. (1990). Changing the insulin receptor to possess insulin-like growth factor-I ligand specificity. Biochemistry 29: 7363–7366. B10-Substituted Insulin Analogues PLoS
    12. (2000). Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.
    13. (1999). Differences in the cellular processing of AspB10 human insulin compared with human insulin LysB28ProB29 human insulin.
    14. (1993). Engineering stability of the insulin monomer fold with application to structureactivity relationships.
    15. (2006). Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant.
    16. (2001). IGF-1 receptor as an alternative receptor for metabolic signaling in insulin receptordeficient muscle cells.
    17. (2007). IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.
    18. (1989). Immunological relationships between receptors for insulin and insulin-like growth factor-I. Evidence for structural heterogeneity of insulin-like growth factor-I receptors involving hybrids with insulin receptors.
    19. (2008). Importance of the solvent-exposed residues of the insulin B chain a-helix for receptor binding.
    20. (2010). In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
    21. (2010). Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling.
    22. (2008). Insulin analogues with increased mitogenic potency - Are they safe?
    23. (2004). Insulin and its receptor: Structure, function and evolution.
    24. (2003). Insulin inhibition of the proteasome is dependent on degradation of insulin by insulindegrading enzyme.
    25. (1973). Insulin interactions with its receptors: Experimental evidence for negative cooperativity.
    26. (1999). Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.
    27. (2009). Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.
    28. (2001). Insulin signalling and the regulation of glucose and lipid metabolism.
    29. (2011). Insulin X10 revisited: a super-mitogenic insulin analogue.
    30. (1990). Insulin-like growth factor-I and factor-II.
    31. (1989). Insulin-like growth factor-I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulinlike growth factor-I and insulin receptor heterodimers.
    32. (1964). Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis.
    33. (1997). Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor.
    34. (1997). Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor.
    35. (2009). Molecular mechanisms of differential intracellular signaling from the insulin receptor.
    36. (1986). Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor.
    37. (1988). Monomeric insulins obtained by protein engineering and their medical implications.
    38. (1983). Purification of insulin receptor with full binding activity.
    39. (1991). Receptor binding and tyrosine kinase activation by insulin analogs with extreme affinities studied in human hepatoma HepG2 cells.
    40. (1980). Role of zinc in insulin biosynthesis: Some possible zinc-insulin interactions in the pancreatic b-cell.
    41. (2010). Safety analysis of basal insulins: Mitogenic potency and receptor binding.
    42. (2008). Scha ¨ffer L
    43. (2007). Selective gene activation by spatial segregation of insulin receptor B signaling.
    44. (1974). Simple free fat cell bioassay for insulin.
    45. (2001). Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors.
    46. (2000). Structure and function of the type 1 insulin-like growth factor receptor.
    47. (2006). Structure of the insulin receptor ectodomain reveals a folded-over conformation.
    48. (1996). Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency.
    49. (1992). The bioactivity of insulin analogs from in vitro receptor binding to in vivo glucose uptake.
    50. (2006). The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity.
    51. (1991). The ligand specificities of the insulin receptor and the insulin-like growth factor-I receptor reside in different regions of a common binding site.
    52. (1994). The structural basis of insulin and insulin-like growth factor-I receptor binding and negative cooperativity, and its relevance to mitogenic versus metabolic signaling.
    53. (1988). The structure of 2Zn pig insulin crystals at 1.5 A ˚ resolution.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.